Result of General Meeting, Renalytix AI PLC, 2020-05-15

RNS Number : 0890N
Renalytix AI PLC
15 May 2020



Renalytix AI plc

(“RenalytixAI”, the “Company”)


Result of General Meeting


Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that at the general meeting of the Company held today the resolution to cancel the share premium account of the Company and to grant the Company the general authority to make market purchases of its own shares were passed. 99.99% (12,665,883 votes) of the votes were cast in favour of the resolution.



The Company is currently making the necessary court applications to enable it to proceed with the share buyback and will issue further updates at the appropriate time.



For further information, please contact:


Renalytix AI plc

James McCullough, CEO

Via Walbrook PR

Stifel (Nominated Adviser & Broker)

Tel: 020 7710 7600

Alex Price / Jonathan Senior / Ben Maddison

N+1 Singer (Joint Broker)

Tel: 020 7496 3000

Aubrey Powell / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]


Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit




Leave a Reply

Your email address will not be published.